Zydus Cadila to launch the biosimilar of Adalimumab in India
Zydus Cadila launched the biosimilar of Adalimumab – the world’s largest selling therapy. Developed by the researchers at the Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name, Exemptia to treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.
This novel non-infringing process for Adalimumab and a novel non-infringing formulation has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a ‘fingerprint match’ with the originator in terms of safety, purity and potency of the product. The biosimilar of adalimumab is a part of Zydus’ robust biologics programme which has the largest number of
monoclonal antibodies under development in India. The group’s R&D pipeline which comprises 24 biologics includes biosimilars and three novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.
Ref: Press Release of Zydus Cadila, Zydus launches world’s first biosimilar of Adalimumab, on 9th of December, 2014.
Great to see an Indian company in top Biosimilar race. Great news for Indian pharma industry.